The purpose was to determine the effectiveness of endothelial-epithelial dystrophy treatment with subconjunctival injection of low molecular weight hyaluronic acid.Prospective material of 14 corneas with different epithelialepithelial dystrophy forms were examined and treated. To study the morphological features of keratopathy with the background of glaucoma staining of histological preparations with hematoxylin and eosin; histochemical staining (PAS reaction, MSB,Masson,Congored; IHC with CD44, MMP9, TGFβ1 were used.According to the results obtained, in the group of patients with EED, with the background of the use of an injectable form of hyaluronic acid, the activity of inflammation decreases due to a decrease in the epithelial and stromal expression of CD44 and MMP9. The proapoptotic and profibrotic action of TGFβ1 decreases.
The efficiency of the treatment of dry eye disease patients with keratopathy at a subconjunctival injection of 1 % sodium hyaluronate was studied. This review describes the functions of hyaluronic acid depending on its molecular weight. The performed study shows the necessity of using the injection form of sodium hyaluronate in the treatment of patients with dry eye disease.
An analysis of changes in the CD44 and MMP9 expression during the keratopathy after corneal inflammatory diseases treatment with injected hyaluronic acid is presented.
Цель: установить характер экспрессии окклюдина и белка плотных контактов 1 в эксплантах роговиц пациентов с хроническими дистрофическими заболеваниями роговицы, а также изменение их экспрессии на фоне применения инъекционной формы 1% натрия гиалуроната. Материалы и методы. В проспективное исследование были включены 37 пациентов с хроническими дистрофическими заболеваниями роговицы: кератопатиями в исходе кератитов (20 случаев) и эндотелиально-эпителиальной дистрофией (17 случаев). Пациенты были разделены на 2 группы. Первая в предоперационном периоде получала курс инъекций 1% низкомолекулярного натрия гиалуроната, вторая не получала дополнительного лечения. Всем включенным в исследование пациентам была выполнена сквозная кератопластика. Выполнено иммуногистохимическое исследование роговичных эксплантов с использованием моноклональных антител к окклюдину и TJP1 с последующей морфометрической оценкой препаратов. Рассчитывались доля пикселей с высокой и умеренной интенсивностью и индекс интенсивности экспрессии в иммунопозитивных участках.Результаты. Позитивность и интенсивность эпителиальной экспрессии окклюдина и белка плотных контактов 1 была статистически значимо ниже в группе ХДЗР в исходе кератитов и имела тенденцию к росту на фоне применения натрия гиалуроната. Позитивность экспрессии окклюдина в эпителии роговицы в группе наследственной ЭЭД была статистически незначимо ниже по сравнению с таковой контрольных эксплантов роговиц и значимо повышалась до нормальных значений на фоне применения натрия гиалуроната. В группе приобретенных ЭЭД выявлены значимо более низкие уровни интенсивности эпителиальной экспрессии окллюдина по сравнению с таковыми группы контроля.Заключение. Применение 1% низкомолекулярного натрия гиалуроната при хронических дистрофических заболеваниях роговицы оказывает благоприятное воздействие на роговичный эпителий благодаря уменьшению воспаления и восстановлению его структурной целостности. При эндотелиально-эпителиальной дистрофии различного генеза субконъюнктивальное введение низкомолекулярного натрия гиалуроната, вероятно, имеет значениедля повышения пролиферативной активности клеток эпителия, в том числе за счет снижения экспрессии белка плотных контактов 1. Purpose: to establish the character of occludin and tight junction protein 1 expression in corneal explants from patients with corneal dystrophies, as well as changes in their expression after 1% sodium hyaluronate injections.Materials and methods. The prospective study included 37 patients with chronic dystrophic diseases of the cornea: keratopathies in the outcome of keratitis (20 cases) and endothelial epithelial dystrophy (17 cases). The patients were divided into 2 groups. The first in the preoperative period received the injections of 1% low molecular weight sodium hyaluronate, the second did not receive additional treatment. All patients included in the study underwent penetrating keratoplasty. Immunohistochemical study of corneal explants was performed using primary monoclonal antibodies to occludin and tight junction protein 1 with subsequent morphometric evaluation of the preparations. The proportion of pixels with high and moderate intensity and the index of expression intensity in immunopositive regions were calculated.Results. The positivity and intensity of epithelial expression of occludin and tight junction protein 1 was statistically significantly lower in the group with corneal dystrophies after keratitis and tended to increase with the use of sodium hyaluronate. The positivity of occludin expression in the corneal epithelium in the hereditary endothelial epithelial group was statistically insignificantly lower than that of the control corneal explants and significantly increased to normal values after sodium hyaluronate injections. In the group of acquired endothelial epithelial dystrophy significantly lower levels of intensity of epithelial expression of occludin were revealed compared to those in the control group.Conclusion. The use of 1% low molecular weight sodium hyaluronate in chronic degenerative diseases of the cornea has a beneficial effect on the corneal epithelium by reducing inflammation and restoring its structural integrity. In endothelial-epithelial dystrophy of various origins, subconjunctival administration of low molecular weight sodium hyaluronate is likely to be important for increasing the proliferative activity of epithelial cells, including by reducing the expression of tight junction protein 1.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.